KOSDAQBiotech & Pharma389470

Inventage Lab

₩28,350▼ 2.91%2026-10-02 close

Market Cap

₩376.6B

Turnover

₩3B

Volume

110,000 shares

Shares out.

13.3M

PER

—

PBR

4.0×

EPS

-₩268

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

DDS Platform Expansion Amid Persistent Losses

Inventage Lab continues to expand partnerships around its long-acting injectable, mRNA-LNP, and subcutaneous reformulation platforms, but revenue remains minimal and operating losses have widened every year.

1
IVL3001, a male-pattern baldness candidate, had its Phase 2 IND filed with Australia's TGA in December 2025, with a domestic MFDS filing reportedly also in progress.
2
Co-development and research agreements with Yuhan, Daewoong Pharmaceutical, and Boehringer Ingelheim continue to broaden the partnership base.
3
Quarterly revenue fell from the KRW 800 million range to below KRW 200 million during 2026, even as operating losses widened over the same period.
4
Net income attributable to owners has swung between profit and loss quarter to quarter, a pattern that appears driven more by non-operating items than by underlying operating performance.
5
Repeated rights offerings and convertible bond issuances have expanded capital, but have also raised concerns about founder-stake dilution and share overhang.

Business structure

Inventage Lab is a drug delivery system (DDS) company that develops long-acting injectables and gene-material delivery platforms based on microfluidics technology.

Its core platforms comprise three pillars: 'IVL-DrugFluidic,' a microsphere manufacturing technology for long-acting injectables; 'IVL-GeneFluidic,' for large-scale mRNA-LNP production; and 'IVL-BioFluidic,' a subcutaneous (SC) reformulation platform that recently entered technical verification.

Its lead pipeline asset is IVL3001, a once-monthly male-pattern baldness treatment being developed clinically with Daewoong Pharmaceutical.

The trial's main goal is to demonstrate efficacy in male-pattern baldness patients and establish the dosing regimen for a Phase 3 trial, with the plan to run trials simultaneously across four domestic and overseas institutions.

Additional pipeline assets include long-acting dementia candidate IVL3003, benign prostatic hyperplasia candidate IVL3013, and GLP-1 class obesity candidates IVL3021 and IVL3024 co-developed with Yuhan.

With global pharma Boehringer Ingelheim, the company has signed a material transfer agreement (MTA) on a metabolic-disease peptide compound followed by a second long-acting injectable co-research agreement.

Manufacturing infrastructure was secured through subsidiary Curatis, in which Inventage Lab is the largest shareholder with a 40.87% stake and cumulative investment of roughly KRW 35 billion.

More recently, the company signed MTAs on its SC reformulation platform with multiple domestic firms and began verification work using actual antibody substances, while also conducting pre-MTA technical reviews with overseas firms in Japan and the United States.

In the competitive landscape, Peptron (SmartDepo) and G2GBio are cited as the main domestic rivals in microsphere-based long-acting technology, and it is confirmed that Boehringer Ingelheim is simultaneously collaborating with both Inventage Lab and G2GBio.

Earnings trend

Quarterly revenue · Operating profit

₩900M-₩8.1B25Q2₩800M-₩7.4B25Q3₩1.1B-₩7.5B25Q4₩400M-₩8.4B26Q1₩200M-₩10.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩3.7B-₩10.9B2022₩700M-₩16B2023₩1.8B-₩19B2024₩2.9B-₩28.4B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩900M	-₩8.1B	−930.7%
2025Q3	₩800M	-₩7.4B	−893.3%
2025Q4	₩1.1B	-₩7.5B	−701.4%
2026Q1	₩400M	-₩8.4B	−2135.2%
2026Q2	₩200M	-₩10.3B	−5851.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩3.7B	-₩10.9B	-₩10.6B	−292.8%	−34.8%	14.5%
2023	₩700M	-₩16B	-₩27B	−2425.1%	−612.0%	924.4%
2024	₩1.8B	-₩19B	-₩17B	−1063.6%	−52.2%	121.9%
2025	₩2.9B	-₩28.4B	-₩8.5B	−965.7%	−13.1%	36.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Annual revenue swung sharply, falling from KRW 3.72 billion in 2022 to KRW 658 million in 2023 before recovering to KRW 1.78 billion in 2024 and KRW 2.94 billion in 2025, indicating the company has yet to establish a stable revenue base.

Operating losses, by contrast, widened every year, from KRW -10.9 billion in 2022 to KRW -16.0 billion in 2023, KRW -19.0 billion in 2024, and KRW -28.4 billion in 2025, with the operating margin reaching -965.7% in 2025.

Equity had shrunk to KRW 4.4 billion in 2023, pushing the debt ratio to 924.4%, but after several rounds of capital raises and the consolidation of Curatis, total equity (owners plus non-controlling interests) rose to KRW 80.9 billion by the end of 2025 while the debt ratio fell to 36.8%.

This equity expansion, however, reflects external financing and subsidiary consolidation rather than an improvement in core operations. Operating cash flow (CFO) was negative every single year from 2022 through 2025, ranging from roughly KRW -5.2 billion to KRW -20.7 billion, underscoring continued cash burn.

On a quarterly basis, net income attributable to owners swung from +KRW 3.45 billion in 2025Q2 to -KRW 4.80 billion in 2025Q3, +KRW 1.05 billion in 2025Q4, +KRW 2.96 billion in 2026Q1, and -KRW 2.35 billion in 2026Q2, even as operating losses steadily deepened from KRW -8.05 billion to KRW -10.28 billion over the same span, highlighting a clear gap between the two lines.

In H1 2026, consolidated revenue fell 45.1% year over year, operating losses grew 39.0%, and net income rose 60.9% according to WiseReport data, suggesting the bottom-line improvement likely stemmed from non-operating factors rather than core business performance.

Over the trailing four quarters (2025Q3 through 2026Q2), cumulative net income attributable to owners totaled KRW -3.14 billion, remaining in loss territory.

Industry analysis

The long-acting injectable (LAI) market is expanding alongside the global boom in GLP-1 class obesity drugs, driving competition to improve dosing convenience through reformulation.

Global pharmaceutical majors are actively exploring co-development and licensing deals with domestic DDS companies alongside their own internal programs, and Novo Nordisk and Eli Lilly, the two leading obesity-drug makers, are both reported to have examined partnerships with Korean firms.

In microsphere-based long-acting technology, Peptron, Inventage Lab, and G2GBio are cited as the leading domestic players, and Boehringer Ingelheim signed a separate formulation development agreement for a long-acting peptide injectable with G2GBio, placing it in a de facto parallel relationship with Inventage Lab.

In mRNA-LNP manufacturing, localizing production systems that have historically relied on foreign equipment has become a key theme, and Inventage Lab presented related research at the CRS conference held in Portugal in July 2026.

The SC (subcutaneous) reformulation platform segment remains at an early stage, with material transfer agreements (MTAs) with multiple domestic firms only recently initiated.

Across the industry, domestic DDS companies still depend more on collaboration fees and milestones than on commercial sales, meaning their revenue contribution is likely to remain limited until actual licensing deals or drug approvals materialize.

Outlook

IVL3001 has completed its Phase 2 IND filing with Australia's TGA, and a domestic MFDS filing during H1 2026 was reportedly planned to run trials simultaneously across four domestic and overseas institutions.

On the manufacturing side, construction of the Osong Bioplant's production facility was completed and trial operations reportedly began in January 2026.

Hana Securities projected in an April 2026 report that the company was in discussions with a global partner during 2026 over a contract manufacturing (CDMO) agreement, which, if concluded, could extend to a scale-out into a European production site; however, this reflects the brokerage's forward view at that time and contract conclusion remains unconfirmed.

On the financing front, thebell reported in March 2026 that the company planned to issue new convertible bonds (CB) and convertible preferred shares (CPS) worth KRW 40 billion each, totaling KRW 80 billion, to fund R&D.

The SC reformulation platform 'IVL-BioFluidic' has entered the stage of verifying actual antibody candidate substances through MTAs with multiple domestic firms, and the CEO stated that while progress varies by project, concrete discussions on subsequent stages could be possible for some projects as early as the first half of 2027. Chong Kun Dang is also reported to be planning a domestic pivotal trial for a related pipeline asset.

Valuation

PER

—

PBR

4.0×

ROE

-4.8%

EPS

-₩268

BPS

₩6,723

Dividend per share

₩0

Inventage Lab remains in a loss-making structure even over the trailing four quarters, meaning a price-to-earnings ratio (PER) cannot be calculated, so valuation discussion centers mainly on the price-to-book ratio (PBR) and the potential value of its pipeline and platforms.

Because calculation methods vary, the company's self-reported PBR differs somewhat from the officially aggregated market PBR, but both indicate trading at a premium to net asset value. No dividend has been paid to date, limiting the usefulness of yield-based peer comparisons.

The fact that a financial structure that came close to capital impairment in 2023 later saw equity expand substantially through several rounds of capital raises and subsidiary consolidation is one backdrop that could influence how the market perceives the premium, but it is worth noting that this expansion stemmed from external financing rather than an improvement in core operations.

Ultimately, how much of the current trading level already reflects the potential outcomes of the clinical and licensing pipeline is a judgment that may differ across investors.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Diversified Global and Domestic Partnerships

The company maintains relationships with multiple partners, including two separate agreements with Boehringer Ingelheim (an MTA and a co-research contract), joint development of a GLP-1 obesity treatment with Yuhan, and clinical collaboration on IVL3001 with Daewoong Pharmaceutical.

Having several partnerships running in parallel can be read as a sign of diversifying its technology-validation channels, though whether each contract will translate into an actual license-out or commercialization remains unconfirmed.

Business Expansion into SC Reformulation Platform

The 'IVL-BioFluidic' platform has entered the stage of verifying actual antibody substances through MTAs with multiple domestic firms. This shows the pipeline expanding beyond its traditional long-acting injectable focus into the new area of antibody and biologic reformulation. The CEO stated that follow-up discussions on some projects could occur as early as the first half of 2027.

Room for CDMO Expansion via Secured Manufacturing Infrastructure

Through the acquisition of Curatis, the company secured an EU-GMP-grade production facility in Osong, which reportedly began trial operations in January 2026.

Hana Securities noted in an April 2026 report that a contract manufacturing (CDMO) agreement was under discussion with a global partner, and stated that if concluded, it could extend to expansion into a European production site; however, this reflects the brokerage's outlook at the time, and confirmation of an actual contract is still needed.

Bear factors

Fragile and Highly Volatile Revenue Base

Quarterly revenue fell sharply in 2026 to KRW 393 million in Q1 and KRW 176 million in Q2, down significantly from KRW 865 million in 2025Q2. Over the same period, operating losses widened instead, to KRW -8.38 billion and KRW -10.28 billion, meaning the profit structure has not improved. Revenue still depends on collaboration and milestone-type income, which drives large quarterly swings.

Gap Between Reported Earnings and Cash Flow

Net income attributable to owners has alternated between profit and loss quarterly, but operating cash flow (CFO) has not been positive in any year from 2022 through 2025.

Even in H1 2026, while net income rose 60.9% year over year, the operating loss widened 39.0% over the same period, suggesting the net income improvement may stem more from non-operating factors than from core business performance. The trailing four-quarter sum of owner net income remains negative.

Repeated Financing and Ownership Dilution

The company has repeatedly conducted rights offerings and convertible bond issuances since its listing, and in March 2026 it was reported to be pursuing an additional KRW 80 billion in CB and CPS issuance.

Over this process, the largest shareholder and related parties' combined stake is understood to have gradually declined from 23.09% at the time of listing. Frequent financing can be read positively as securing R&D funding, but it also carries share overhang concerns.

Risk factors

Clinical and Regulatory Risk

The lead pipeline asset IVL3001 is still at the Phase 2 IND filing stage, and other candidates such as IVL3003 remain in early-stage clinical trials. Delays or failures in trial results, or delays in regulatory approval, could directly affect company value. Commercialization would require multiple further clinical stages and considerable time.

Capital Structure and Liquidity Risk

The company has recorded negative operating cash flow every year and continues to rely on external financing. There is also a risk that financial burdens at subsidiary Curatis could transfer to the parent, given that Curatis accounts for a substantial share of consolidated assets. Further CB issuances or rights offerings could result in additional ownership dilution.

Competitive and Partnership Uncertainty

It has been confirmed that Boehringer Ingelheim signed a separate long-acting injectable development agreement with G2GBio in addition to its partnership with Inventage Lab.

While this can be interpreted as a common practice of global pharma companies collaborating with multiple domestic firms simultaneously, it also shows that any single partnership does not necessarily lead to an exclusive licensing outcome. Competition with domestic rivals Peptron and G2GBio over technology and contracts is expected to continue.

What to watch next

Around November 2026
Watch the 2026 Q3 earnings disclosure to check whether revenue recovers and how the operating loss trend evolves.
During H2 2026
Check whether IVL3001 receives MFDS IND approval domestically and whether the simultaneous trial across four domestic and overseas institutions begins.
H2 2026 to year-end
Track the outcome of the CDMO contract discussions with a global partner mentioned by Hana Securities, and the operating status of the Osong Bioplant.
H1 2027
Check whether follow-up stage discussions materialize for some IVL-BioFluidic projects, as referenced by CEO Kim Ju-hee.
At each future disclosure
Continue monitoring for any additional CB issuances or rights offerings, and the resulting changes in the largest shareholder's stake and share overhang size.

Overall view

Inventage Lab is broadening its business base around a microfluidics-based DDS platform, securing multiple partnerships with Daewoong Pharmaceutical, Yuhan, and Boehringer Ingelheim, among others.

However, annual revenue still hovers around KRW 3 billion, and operating losses have widened every year, from KRW -10.9 billion in 2022 to KRW -28.4 billion in 2025.

Net income attributable to owners has swung between profit and loss quarterly, while operating cash flow has been negative for four consecutive years, leaving open the possibility that earnings improvements are driven more by non-operating factors than by core business performance.

A financial structure that came close to capital impairment in 2023 has since stabilized through repeated capital raises, but this came at the cost of largest-shareholder dilution and share overhang concerns.

Numerous events remain to be confirmed going forward, including IVL3001's Phase 2 entry, progress on SC platform MTAs, and the ramp-up of the Osong production facility, warranting continued monitoring of both earnings and pipeline progress.

The investment judgment on how to weigh this business expansion against the financial vulnerabilities is a matter for readers to decide for themselves.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.